Remdesivir to come in oral formulation; drug regulator s nod awaited
Jubilant Pharma says oral formulation is an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients
BusinessToday.In | April 19, 2021 | Updated 13:13 IST
Remdesivir is the first and the only antiviral drug fully approved by the US FDA
Jubilant Pharma Limited, a subsidiary of Jubilant Pharmova Limited, has completed safety trials in animals and healthy human volunteers in India using a novel oral formulation of remdesivir, which is likely to be more effective and viable than the commercially available injectable formulation. Jubilant has now sought approval for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI).
Remdesivir only for hospitalised patients low on oxygen, says Health Ministry It is an investigational drug. Its role has been clearly defined in the clinical management protocol. There is no question of the use of Remdesivir in home settings, said NITI Aayog member Dr V K Paul
BusinessToday.In | April 14, 2021 | Updated 11:46 IST
Govt says Remdesivir only for emergency uses
Amid the current surge in the number of coronavirus cases, several states have reported a shortage of anti-viral drug Remdesivir. The Health Ministry urged hospitals to use the drug judiciously and rationally. The ministry said that Remdesivir should be supplied only to hospitals and not to chemists or patients. The ministry said that the drug must be given only to hospitalised patients who are low on oxygen.